Table 3 Baseline pain severity at first and at second dose for rescue and recurrence populations and overall
POPULATION - Baseline pain severity | Placebo | Lasmiditan 50 mg | Lasmiditan 100 mg | Lasmiditan 200 mg | ||||
|---|---|---|---|---|---|---|---|---|
At First Dose | At Second Dose | At First Dose | At Second Dose | At First Dose | At Second Dose | At First Dose | At Second Dose | |
RESCUE | N = 606 | N = 245 | N = 388 | N = 310 | ||||
- Severea | 174 (28.7) | 144 (23.8) | 72 (29.4) | 57 (23.3) | 124 (32.0) | 84 (21.6) | 101 (32.6) | 75 (24.2) |
- Moderate | 428 (70.6) | 332 (54.8) | 170 (69.4) | 127 (51.8) | 258 (66.5) | 179 (46.1) | 206 (66.5) | 152 (49.0) |
- Mild | 4 (0.7) | 130 (21.5) | 3 (1.2) | 61 (24.9) | 6 (1.5) | 124 (32.0) | 3 (1.0) | 83 (26.8) |
- None | – | 0 | – | 0 | – | 1 (0.3) | – | 0 |
RECURRENCE | N = 21 | N = 13 | N = 35 | N = 28 | ||||
- Severe | 4 (19.0) | 1 (4.8) | 3 (23.1) | 3 (23.1) | 6 (17.1) | 5 (14.3) | 10 (35.7) | 7 (25.0) |
- Moderate | 16 (76.2) | 14 (66.7) | 9 (69.2) | 9 (69.2) | 29 (82.9) | 23 (65.7) | 18 (64.3) | 19 (67.9) |
- Mild | 1 (4.8) | 5 (23.8) | 1 (7.7) | 1 (7.7) | 0 | 4 (11.4) | 0 | 2 (7.1) |
- None | – | 1 (4.8) | – | 0 | – | 3 (8.6) | – | 0 |
OVERALLb | N = 1130 | N = 598 | N = 1133 | N = 1120 | ||||
- Severe | 331 (29.3) | 165 (27.6) | 324 (28.6) | 327 (29.2) | ||||
- Moderate | 782 (69.2) | 421 (70.4) | 794 (70.1) | 771 (68.8) | ||||
- Mild | 16 (1.4) | 12 (2.0) | 15 (1.3) | 22 (2.0) | ||||
- None | 1 (0.1) | 0 | 0 | 0 | ||||